ACTU: Oral elraglusib advances with strong efficacy, synergy in combinations, and pivotal pediatric trials
Elraglusib, a GSK-3β inhibitor, demonstrated significant survival benefits in metastatic pancreatic cancer and is advancing to an oral formulation to improve patient outcomes and enable daily dosing. The strategy includes combination regimens with RAS inhibitors, expansion into multiple cancers, an…